Efficacy and Tolerability of Ombitasvir/Paritaprevir/Ritonavir in HCV Genotype 1-infected Elderly Japanese Patients

Pinzone, 2014, Cirrhotic patients are still at risk of developing hepatocellular carcinoma despite Interferon-induced sustained virological response., Eur Rev Med Pharmacol Sci, 18, 11 Moon, 2015, Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin., Dig Dis Sci, 60, 573, 10.1007/s10620-014-3361-6 von Kockritz, 2017, Management of chronic hepatitis C in 2017., Hamostaseologie, 37, 186, 10.5482/HAMO-16-07-0019 Latt, 2012, Hepatitis C virus and its renal manifestations: a review and update., Gastroenterol Hepatol, 8, 434 Holmes, 2015, Interferon-free combination therapies for the treatment of hepatitis C: current insights., Hepat Med, 7, 51, 10.2147/HMER.S55864 Flisiak, 2017, Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C., Expert Rev Gastroenterol Hepatol, 11, 559, 10.1080/17474124.2017.1309284 Johnson, 2016, Economic evaluation of ombitasvir/paritaprevir/ ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis C virus infection., J Med Econ, 19, 983, 10.1080/13696998.2016.1189920 Fabrizi, 2012, Hepatitis C virus infection and dialysis: 2012 update., ISRN Nephrol, 2013, 159760 Alseiari, 2016, Evidence underlying KDIGO (Kidney Disease: Improving Global Outcomes) guideline recommendations: a systematic review., Am J Kidney Dis, 67, 417, 10.1053/j.ajkd.2015.09.016 Kumada, 2015, Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis., Hepatology, 62, 1037, 10.1002/hep.27972 Dreisbach, 2008, The effect of chronic renal failure on drug metabolism and transport., Expert Opin Drug Metab Toxicol, 4, 1065, 10.1517/17425255.4.8.1065 Alshogran, 2016, Implications of Kidney Disease on Metabolic Reduction., Curr Drug Metab, 17, 663, 10.2174/1389200217666160603131320 Alshogran, 2015, Effect of experimental kidney disease on the functional expression of hepatic reductases., Drug Metab Dispos, 43, 100, 10.1124/dmd.114.061150 Tani, 2017, The effects of increasing calcium channel blocker dose vs. adding a diuretic to treatment regimens for patients with uncontrolled hypertension., Hypertens Res, 40, 892, 10.1038/hr.2017.56 Sueta, 2017, Clinical roles of calcium channel blockers in ischemic heart diseases., Hypertens Res, 40, 423, 10.1038/hr.2016.183 Michaud, 2008, Effect of hemodialysis on hepatic cytochrome P450 functional expression., J Pharmacol Sci, 108, 157, 10.1254/jphs.08042FP Pockros, 2016, Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease., Gastroenterology, 150, 1590, 10.1053/j.gastro.2016.02.078 Munoz-Gomez, 2017, Therapy with ombitasvir/ paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience., J Viral Hepat, 24, 464, 10.1111/jvh.12664 Morisawa, 2017, Effectiveness of a fixed combination formula of ombitasvir/paritaprevir/ritonavir for hepatitis C virus infection in patients on maintenance haemodialysis., Nephrology (Carlton), 22, 562, 10.1111/nep.13011 Larrey, 2014, Patient adherence issues in the treatment of hepatitis C., Patient Prefer Adherence, 8, 763, 10.2147/PPA.S30339